James Crowe Archive — Page 4 of 13

VUMC NEWS logo in white lettering inside a cyan and yellow outlined square on a blue gradient background.
November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Dark, thin, curved line forming a stylized abstract shape with two loops on a textured blue background.
October 28, 2021

VUMC researchers a step closer to broad ebolavirus protection

Green-gloved laboratory worker holds two small tubes containing clear liquid over a blurred lab coat.
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

Illustration of several spherical virus particles with brown textured surfaces and numerous translucent yellow spike-like projections, shown against a dark reddish-brown background.
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Green-gloved laboratory worker holds two small tubes containing clear liquid over a blurred lab coat.
September 8, 2021

VUMC antibodies help neutralize two deadly viruses: study

Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.

Green-gloved laboratory worker holds two small tubes containing clear liquid over a blurred lab coat.
August 20, 2021

COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.